Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.43 |
| ▸ | CA1 | P00915 | 3/20 | 0.43 |
| ▸ | CA2 | P00918 | 3/20 | 0.43 |
| ▸ | CA9 | Q16790 | 3/20 | 0.43 |
| ▸ | PYGB | P11216 | 7/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26135776 | 1.00 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL4292200 | 1.00 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL31150424 | 1.00 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL20265935 | 1.00 | CA12 (0.43) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28448246 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28444663 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL734876 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28448523 | 0.83 | CA12 (0.44) | CA12CA1CA2CA9PYGB | |
| SCHEMBL9346601 | 0.81 | CA12 (0.42) | CA12CA1CA2CA9PYGB | |
| SCHEMBL28732847 | 0.81 | PYGB (0.48) | CA12CA1CA2CA9PYGB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4010007-B1 | PRODUCTION OF MHC II/CII COMPLEXES | FRAUNHOFER GES FORSCHUNG (DE) | 2023-11-15 | — | — | EP | claimed |
| US-20220288177-A1 | PRODUCTION OF MHC II/CII COMPLEXES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-09-15 | — | — | US | claimed |
| EP-4010006-A1 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-06-15 | — | — | EP | claimed |
| EP-4010007-A1 | PRODUCTION OF MHC II/CII COMPLEXES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-06-15 | — | — | EP | claimed |
| CN-114206945-A | Production of MHC II/CII peptide complexes | 弗劳恩霍夫应用研究促进协会 | 2022-03-18 | — | — | CN | claimed |
| US-12622946-B2 | HLA-DR/CII peptide complexes for treating arthritis | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2026-05-12 | — | — | US | disclosed |
| US-20250207168-A1 | PRODUCTION CELLS | HOFFMANN-LA ROCHE INC. (US) | 2025-06-26 | — | — | US | disclosed |
| EP-4532526-A1 | IMPROVED PRODUCTION CELLS | F. Hoffmann-La Roche AG (CH) | 2025-04-09 | — | — | EP | disclosed |
| CN-119630690-A | Improved producer cells | 豪夫迈·罗氏有限公司 | 2025-03-14 | — | — | CN | disclosed |
| US-20250032591-A1 | PHARMACEUTICAL COMPOSITIONS AND METHODS FOR TREATING CONNECTIVE TISSUE CONDITIONS WITH COLLAGEN POLYPEPTIDES | GELTOR, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240415757-A1 | ANIMAL-FREE COSMETIC COLLAGENS | GELTOR, INC. | 2024-12-19 | — | — | US | disclosed |
| CN-118750607-A | HLA-DR/CII peptide complexes for the treatment of arthritis | 弗劳恩霍夫应用研究促进协会 | 2024-10-11 | — | — | CN | disclosed |
| US-20220332775-A1 | ANIMAL-FREE DIETARY COLLAGEN | GELTOR, INC. | 2022-10-20 | — | — | US | disclosed |
| US-20220288177-A1 | PRODUCTION OF MHC II/CII COMPLEXES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-09-15 | — | — | US | disclosed |
| US-20220280599-A1 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-09-08 | — | — | US | disclosed |
| EP-4010006-A1 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-06-15 | — | — | EP | disclosed |
| EP-4010007-A1 | PRODUCTION OF MHC II/CII COMPLEXES | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. (DE) | 2022-06-15 | — | — | EP | disclosed |
| US-11332505-B2 | Animal-free dietary collagen | GELTOR, INC. (US) | 2022-05-17 | — | — | US | disclosed |
| CN-114302743-A | HLA-DR/CII peptide complexes for the treatment of arthritis | 弗劳恩霍夫应用研究促进协会 | 2022-04-08 | — | — | CN | disclosed |
| CN-114206945-A | Production of MHC II/CII peptide complexes | 弗劳恩霍夫应用研究促进协会 | 2022-03-18 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220288177-A1 | PRODUCTION OF MHC II/CII COMPLEXES | HLA-DRB1, MICA, CD74 | CA12 556/4885CA1 1508/4885CA2 3505/4885 |
| US-12622946-B2 | HLA-DR/CII peptide complexes for treating arthritis | HLA-DRB1, MICA, CD74 | CA12 2982/4885CA1 2768/4885CA2 3479/4885 |
| US-20220280599-A1 | HLA-DR/CII PEPTIDE COMPLEXES FOR TREATING ARTHRITIS | HLA-DRB1, CD74, HLA-C | CA12 1416/4885CA1 1558/4885CA2 2706/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.